Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 19/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | CSF1R | P07333 | 1/20 | 0.68 |
| ▸ | RET | P07949 | 1/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.68 |
| ▸ | KIT | P10721 | 1/20 | 0.68 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.68 |
| ▸ | CDK11B | P21127 | 1/20 | 0.68 |
| ▸ | CCNC | P24863 | 1/20 | 0.68 |
| ▸ | FLT4 | P35916 | 1/20 | 0.68 |
| ▸ | CDK8 | P49336 | 1/20 | 0.68 |
| ▸ | BTK | Q06187 | 1/20 | 0.68 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.68 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.68 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.68 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19683620 | 0.94 | FLT3 (0.68) | FLT3LCKCSF1RRETPDGFRB | |
| SCHEMBL19683831 | 0.92 | FLT3 (0.66) | FLT3LCKCSF1RRETPDGFRB | |
| SCHEMBL20873190 | 0.92 | FLT3 (0.66) | FLT3LCKCSF1RRETPDGFRB | |
| SCHEMBL20873193 | 0.91 | FLT3 (0.68) | FLT3LCKCSF1RRETPDGFRB | |
| SCHEMBL19683625 | 0.90 | FLT3 (0.65) | FLT3LCKCSF1RRETPDGFRB | |
| SCHEMBL19683595 | 0.90 | FLT3 (0.70) | FLT3LCKCSF1RRETPDGFRB | |
| SCHEMBL19683864 | 0.89 | FLT3 (0.69) | FLT3LCKCSF1RRETPDGFRB | |
| SCHEMBL19683593 | 0.89 | FLT3 (0.69) | FLT3LCKCSF1RRETPDGFRB | |
| SCHEMBL20873203 | 0.89 | FLT3 (0.66) | FLT3LCKCSF1RRETPDGFRB | |
| SCHEMBL19683763 | 0.89 | FLT3 (0.66) | FLT3LCKCSF1RRETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975082-B2 | Inhibitor of FLT3 kinase and use thereof | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2021-04-13 | — | — | US | disclosed |
| US-10975082-B2 | Inhibitor of FLT3 kinase and use thereof | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2021-04-13 | — | — | US | disclosed |
| EP-3466952-B1 | 1-(4-(4-AMINO-3-PHENYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)-PHENYL)-UREA DERIVATIVES AS FLT3 KINASE INHIBITORS FOR TREATING CANCER | PRECEDO PHARMACEUTICALS CO LTD (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3466952-B1 | 1-(4-(4-AMINO-3-PHENYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)-PHENYL)-UREA DERIVATIVES AS FLT3 KINASE INHIBITORS FOR TREATING CANCER | PRECEDO PHARMACEUTICALS CO LTD (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3466952-A1 | NOVEL INHIBITOR FOR FLT3 KINASE AND USES THEREOF | Precedo Pharmaceuticals Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| EP-3466952-A1 | NOVEL INHIBITOR FOR FLT3 KINASE AND USES THEREOF | Precedo Pharmaceuticals Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017206962-A1 | NOVEL INHIBITOR FOR FLT3 KINASE AND USES THEREOF | 合肥中科普瑞昇生物医药科技有限公司 | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975082-B2 | Inhibitor of FLT3 kinase and use thereof | FLT3, FLT1, FGFR1 | FLT3 1/4885LCK 136/4885CSF1R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.